Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma

Oliva, 2020, Clinical applications and future directions of minimal residual disease testing in multiple Myeloma, Front Oncol, 10, 1, 10.3389/fonc.2020.00001 Munshi, 2020, A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma, Blood Adv, 4, 5988, 10.1182/bloodadvances.2020002827 Burgos, 2020, Measurable residual disease in multiple myeloma: ready for clinical practice?, J Hematol Oncol, 13, 82, 10.1186/s13045-020-00911-4 Avet-Loiseau, 2020, Minimal residual disease status as a surrogate endpoint for progression-free survival in newly diagnosed multiple myeloma studies: a meta-analysis, Clin Lymphoma Myeloma Leuk, 20, e30, 10.1016/j.clml.2019.09.622 Paiva, 2020, Measurable residual disease by next-generation flow cytometry in multiple myeloma, J Clin Oncol, 38, 784, 10.1200/JCO.19.01231 Costa, 2021, Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma, J Clin Oncol, 40, 2901, 10.1200/JCO.21.01935 Bhutani, 2020, Response-adaptive phase II study of daratumumab combined with carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma, Blood, 136, 38, 10.1182/blood-2020-138485 Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma workshop consensus panel 1, Blood, 117, 4691, 10.1182/blood-2010-10-299487 Krzywdzinska, 2021, Harmonization of flow cytometric minimal residual disease assessment in multiple myeloma in centers of polish myeloma consortium, Diagnostics (Basel), 11 Medina, 2020, Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma, Blood Cancer J, 10, 108, 10.1038/s41408-020-00377-0 Kriegsmann, 2020, Comparison of NGS and MFC methods: key metrics in multiple myeloma MRD assessment, Cancers (Basel), 12, 10.3390/cancers12082322 Oliva, 2019, Minimal residual disease evaluation by multiparameter flow cytometry and next generation sequencing in the forte trial for newly diagnosed multiple myeloma patients, Blood, 134, 4322, 10.1182/blood-2019-124645 Paiva, 2010, Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders, Cytometry B Clin Cytom, 78, 239, 10.1002/cyto.b.20512 Flores-Montero, 2016, Immunophenotype of normal vs. myeloma plasma cells: toward antibody panel specifications for MRD detection in multiple myeloma, Cytometry B Clin Cytom, 90, 61, 10.1002/cyto.b.21265 Flores-Montero, 2017, Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma, Leukemia, 31, 2094, 10.1038/leu.2017.29 Soh, 2022, Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: an international harmonized approach for data analysis, Cytometry B Clin Cytom, 102, 88, 10.1002/cyto.b.22053 Soh, 2021, Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: current paradigm, guidelines, and future applications, Int J Lab Hematol, 43, 43, 10.1111/ijlh.13562 Davis, 2013, Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part I - rationale and aims, Cytometry B Clin Cytom, 84, 282, 10.1002/cyto.b.21104 Martinez-Lopez, 2020, Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma, Blood Adv, 4, 3295, 10.1182/bloodadvances.2020002037 Baumer, 2018, Exploring DNA quality of single cells for genome analysis with simultaneous whole-genome amplification, Sci Rep, 8, 7476, 10.1038/s41598-018-25895-7 Puig, 2021, Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma, Cancers (Basel), 13, 10.3390/cancers13194924 Katz, 2010, Adhesion molecules–The lifelines of multiple myeloma cells, Semin Cancer Biol, 20, 186, 10.1016/j.semcancer.2010.04.003 Hosen, 2020, Integrins in multiple myeloma, Inflamm Regen, 40, 4, 10.1186/s41232-020-00113-y Chang, 2020, CT-guided bone marrow aspirations and biopsies: retrospective study and comparison with blind procedures, Skeletal Radiol, 49, 1285, 10.1007/s00256-020-03423-x